关键词：α-1抗胰蛋白酶；肝脏中产生；糖蛋白；炎症过程；分解蛋白质
摘 要：Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein produced in the liver that helps in the inactivation of enzymes such as elastase, which break down proteins during inflammation induced by some injury. The decline in alpha-1 antitrypsin levels in the blood results in a rare genetic condition known as alpha-1 antitrypsin deficiency (AATD), which leads to the development of respiratory and liver diseases, and severe skin infections. The disease is passed on from parents to an offspring through mutated genes. Augmentation therapy using drugs derived from human plasma helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the condition.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Overview: Alpha-1 antitrypsin deficiency

Pathophysiology

Symptoms

Diagnosis

Management

PART 06: Overview: Alpha-1 antitrypsin drugs

Components of blood plasma

Regulation of plasma therapeutics

Regulatory authorities

Reimbursement

PART 07: Pipeline analysis

D1-AAT

B1-AAT

C1-AAT

rAAV1-CB-hAAT

G1-AAT

L1-AAT

ARC-AAT

AAT

PTB-101 SDF Alpha

ALN-AAT

PART 08: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 09: Market segmentation by route of

administration

Parenteral

Inhalation

PART 10: Geographical segmentation

Global alpha-1 antitrypsin drugs market by geography

2015-2020

Alpha-1 antitrypsin drugs market in Americas

Alpha-1 antitrypsin drugs market in EMEA

Alpha-1 antitrypsin drugs market in APAC

PART 11: Market drivers

Improved diagnosis of AATD

Improving economic conditions

Novel product opportunities

High unmet needs

PART 12: Impact of drivers

PART 13: Market challenges

Stringent regulations

Limited plasma fractionation capacity

Shortage of alpha-1 antitrypsin supply

High cost of drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

Strategic alliances and M&A

Patient assistance programs

Increasing awareness about therapy

PART 16: Vendor landscape

Competitive scenario

Market share analysis 2015

Baxter International

CSL Behring

Grifols

Kamada

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio